Today: 16 May 2026
CrowdStrike Stock Gets Morgan Stanley Upgrade as Strong Outlook Blunts AI Fears

CrowdStrike Stock Gets Morgan Stanley Upgrade as Strong Outlook Blunts AI Fears

NEW YORK, March 10, 2026, 3:43 PM EDT.

CrowdStrike Holdings was little changed in afternoon trading on Tuesday after Morgan Stanley upgraded the cybersecurity company to overweight and raised its price target. The shares were at $434.25, up 12 cents from a previous close of $434.13, after a six-session winning streak through Monday.

The call matters because CrowdStrike has become a test of whether new AI tools will eat into parts of the cybersecurity market or push customers toward bigger software platforms. CrowdStrike, Zscaler and other cyber names sold off in late February after Anthropic launched Claude Code Security, though JPMorgan strategists later said investors had been pricing in a worst-case disruption scenario.

Barron’s, citing Morgan Stanley’s note, said the bank lifted its price target to $510 from $487. Excerpts published Tuesday said analysts Meta A. Marshall and Keith Weiss saw CrowdStrike as staying “in rarified air” among software companies still growing more than 20% at scale. Barron’s

CrowdStrike gave bulls fresh numbers on March 3. It forecast fiscal 2027 revenue of $5.87 billion to $5.93 billion, above analysts’ estimates, as fourth-quarter revenue rose 23% to $1.31 billion. “I think people are still digesting numbers. But in this environment, having a software stock trade close to flat post print seems like a good outcome,” Truist Securities analyst Junaid Siddiqui told Reuters. The company also said costs tied to the July 2024 Windows outage and related matters rose to $117.7 million in fiscal 2026, though they narrowed in the latest quarter. Reuters

In its earnings release, Chief Executive George Kurtz said fiscal 2026 would “go down in our history books as CrowdStrike’s best year yet” after the company reached $5.25 billion in annual recurring revenue, or subscription revenue normalized over a year. He also said AI adoption was making CrowdStrike “mission-critical infrastructure.” Securities and Exchange Commission

CrowdStrike is still fighting for security budgets against larger platform vendors such as Palo Alto Networks and cloud-security rival Zscaler. Palo Alto last month cut its annual adjusted profit forecast as deal costs rose, while Zscaler reported a wider quarterly loss in what Reuters described as a competitive market.

But the trade still has an obvious weak spot. Excerpts published by Investing.com said Morgan Stanley argued CrowdStrike’s premium valuation versus peers had to be backed by reaccelerating growth and free-cash-flow margins above 30%. That leaves little room for a stumble if customer spending softens or AI tools start to pressure pricing.

CrowdStrike has also been widening its reach beyond endpoint protection, software that secures laptops and servers. Reuters reported in January that it agreed to buy identity-security startup SGNL for $740 million and browser security firm Seraphic Security for about $420 million, and a separate Reuters report on Monday said it had sued rival AiStrike in California federal court over alleged trademark infringement.

Stock Market Today

  • W. R. Berkley (WRB) Shows 45.9% Undervaluation Despite Recent Price Stability
    May 15, 2026, 7:55 PM EDT. W. R. Berkley (WRB) stock has shown limited movement recently with a 1.2% gain over 7 days and a 4.2% decline year-to-date. Analysts use valuation methods like Excess Returns, which estimates intrinsic value by calculating profits above shareholder required returns. With an intrinsic value estimate of $122.79 against a current price near $66.45, the stock appears 45.9% undervalued. The insurer's steady underwriting profile and capital discipline contrast with sector concerns on insurance pricing and interest rate sensitivity. WRB currently scores 2 out of 6 on valuation metrics, highlighting potential but raising caution.

Latest articles

Accuray inks 10-year cancer tech agreement, shares in focus

Accuray inks 10-year cancer tech agreement, shares in focus

16 May 2026
Accuray and the University of Wisconsin School of Medicine and Public Health signed a 10-year research agreement focused on Accuray’s Stellar adaptive radiotherapy platform. The announcement came after market close, with Accuray shares ending down 5.2% at $0.27. The deal follows Accuray’s recent withdrawal of fiscal 2026 guidance and ongoing financial pressures.
Origin Materials Gains as Filing Signals $3.54 Liquidation Payout Possible

Origin Materials Gains as Filing Signals $3.54 Liquidation Payout Possible

16 May 2026
Origin Materials asked shareholders to approve a plan to liquidate and dissolve the company, estimating an initial payout of $0.61 to $3.54 per share depending on asset sales and claims. Shares rose 15% to $1.43 after the filing. The company reported a 91% drop in first-quarter revenue and warned it may not survive without the wind-down. Origin cut 59% of its workforce and CEO John Bissell stepped down May 1.
NextNRG Q1 Revenue Gains, but Company Holds Cash Warning

NextNRG Q1 Revenue Gains, but Company Holds Cash Warning

16 May 2026
NextNRG reported first-quarter revenue of $21.1 million, up 29% from a year earlier, but its net loss widened to $10.8 million. Cash fell to $208,048 at quarter-end, and management warned it needs immediate capital to continue operations. Shares closed at $0.2804 on Nasdaq, down nearly 6%. Total liabilities reached $34.3 million, with a stockholders’ deficit of $22 million.
HCW Biologics jumps 262% after Trimmune deal, Q1 profit, Nasdaq risk update

HCW Biologics jumps 262% after Trimmune deal, Q1 profit, Nasdaq risk update

16 May 2026
HCW Biologics shares jumped 262% to $1.22 Friday after the company posted a $3.47 million first-quarter profit, driven by a $6.5 million licensing deal with Beijing Trimmune Biotech. The company faces a possible Nasdaq delisting and will ask shareholders to approve a reverse stock split on June 15. HCW plans to report early Phase 1 data for its alopecia drug in the first half of 2026.
Procter & Gamble Makes Nearly $1 Billion Gillette Boston HQ Bet as Growth Pressures Rise
Previous Story

Procter & Gamble Makes Nearly $1 Billion Gillette Boston HQ Bet as Growth Pressures Rise

KLA Corporation stock rises as Barclays lifts chip-equipment outlook ahead of investor day
Next Story

KLA Corporation stock rises as Barclays lifts chip-equipment outlook ahead of investor day

Go toTop